Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. pursuant and/or traceable to Kyverna's initial public offering conducted on ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public ...

Kyverna Therapeutics, Inc. has a 52-week low of $3.02 and a 52-week high of $35.06. The business’s 50 day moving average is $4.00 and its two-hundred day moving average is $5.48.

The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. . Shareholders who purchased shares ...

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: This lawsuit is on behalf of all ...

IF YOU ARE AN INVESTOR WHO LOST MONEY ON KYVERNA THERAPEUTICS, INC. (KYTX), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On or about February 8, 2024, Kyverna ...

Glancy Prongay & Murray LLP reminds investors of the upcoming February 7, 2025 deadline to file a lead plaintiff motion in the ...

Kyverna Therapeutics Inc. (KYTX) stock has reached a new 52-week low, trading at $2.78, down 10.4% in the past week alone, as the biotechnology firm faces a challenging market environment. According ...